Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Plasma Hydrogen Sulfide, Nitric Oxide and Stress Hyperglycemia in Acute Myocardial Infarction

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03829605
Recruitment Status : Not yet recruiting
First Posted : February 4, 2019
Last Update Posted : February 4, 2019
Sponsor:
Information provided by (Responsible Party):
Reham I El-mahdy, Assiut University

Brief Summary:
Acute myocardial infarction (AMI) can cause heart failure, an irregular heartbeat, cardiogenic shock, or cardiac arrest. It is the major cause of morbidity and mortality in the general population. The diagnosis of AMI is complex basing on the clinical history, physical examination, cardiac markers, and a chest radiograph. Besides, considering that the mechanisms linking activation of inflammation and ACS are complex as well, progress in diagnosis and therapy improves little

Condition or disease Intervention/treatment
Myocardial Infarction Other: Measurement of hydrogen sulfide

Detailed Description:
The World Health Organization (WHO) indexed cardiovascular disease (CVD) as a leading foundation for human death in developing as well as developed countries. Ischemic necrosis of the myocardium is called myocar¬dial infarction. Despite improvements in medical and interventional therapies in recent years, acute myocar¬dial infarction is still an important cause of mortal¬ity and morbidity. Hydrogen sulfide (H2S) is a colorless, water-soluble gas and is an endogenously produced labile diffusible mediator with multiple roles in the cardiovascular system in health and disease. H2S is endogenously generated, and cystathionine-β-synthase (CBS), cystathionine-γ-lyase (CSE), and 3-mercaptopyruvate sulfurtransferase (3-MST) are key enzymes involved in its biological production. Once interacting with carbon monoxide and nitric oxide, H2S will initiate a unique gaseous signaling net¬work and participate in the regulation of multiple patho¬physiological processes. Plasma H2S levels negatively correlated with HbA1c, duration of diabetes, and systolic and diastolic blood pressures.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 50 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Plasma Measurement of Hydrogen Sulfide, Nitric Oxide and Stress Hyperglycemia in Acute Myocardial Infarction
Estimated Study Start Date : February 15, 2019
Estimated Primary Completion Date : April 20, 2019
Estimated Study Completion Date : May 20, 2019

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Group I:
Fifty AMI patients on admission
Other: Measurement of hydrogen sulfide
Hydrogen sulfide will be measured by ELISA and correlated with nitric oxide and hyperglycemia

Group II:
The previous AMI patients after 12 hours
Other: Measurement of hydrogen sulfide
Hydrogen sulfide will be measured by ELISA and correlated with nitric oxide and hyperglycemia




Primary Outcome Measures :
  1. The mean difference of hydrogen sulfide before and after treatment [ Time Frame: 12 hours ]
    Hydrogen sulfide mean difference will be measured by ELISA in myocardial infarction.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Acute myocardial infarction
Criteria

Inclusion Criteria:

  • Patients with confirmed diagnosis of AMI-
  • Patients of age 18 years or more who are willing to participate in the study and give their consent for same.

Exclusion Criteria:

  • Patients with congenital heart diseases, alcoholics with a past history of liver disease, pulmonary embolus, sepsis, chest trauma, and renal failure were excluded from the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03829605


Contacts
Layout table for location contacts
Contact: reham elmahdy, Dr +201002714637 reham.elmahdy@aun.edu.eg

Sponsors and Collaborators
Assiut University

Publications:
Layout table for additonal information
Responsible Party: Reham I El-mahdy, Principal Investigator, Assiut University
ClinicalTrials.gov Identifier: NCT03829605     History of Changes
Other Study ID Numbers: Myocardial infarction
First Posted: February 4, 2019    Key Record Dates
Last Update Posted: February 4, 2019
Last Verified: February 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Reham I El-mahdy, Assiut University:
Hydrogen sulfide
Nitric oxide
Stress hyperglycemia
Acute coronary syndrome
Additional relevant MeSH terms:
Layout table for MeSH terms
Myocardial Infarction
Hyperglycemia
Infarction
Ischemia
Pathologic Processes
Necrosis
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Nitric Oxide
Hydrogen Sulfide
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Free Radical Scavengers
Antioxidants
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Endothelium-Dependent Relaxing Factors
Vasodilator Agents
Gasotransmitters
Protective Agents